Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.
confirmed MASLD at abdominal imaging
confirmed excessive muscle lipid content at imaging
stable weight
severe comorbidities including active malignancies, neuromuscular degenerative diseases
contraindications to physical activity
excessive alcohol consumption
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead sponsor
Concerted Research Action
Collaborator
Fonds National de la Recherche Scientifique
Collaborator